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Abstract
When diagnosed with ALL the age group between 18 and 45 years old (AYA,
adolescents and young adults) do not have the good prognosis factors generally
observed in children with this diagnosis. For a long time, it was undetermined
whether they should be treated with continuous and sustained chemotherapy as
children or whether receive sustained chemotherapy, but with longer rest periods
like old adults. The medical care of adolescents and young adults with neoplastic
diseases, grouped between 15 and 45 years of age, became an emerging research
field of treatment in hematological diseases. Outcomes have asses complete
response disease-free survival, and overall survival as markers of response, with
very poor results reported. Relevant challenges have been identified in the AYA
group with ALL that have drawn attention to the need to increase research in this
area, particularly in the care of the population under 45 years of age with
hematological malignancies.
Keywords: acute lymphoblastic leukemia, remission, relapse, treatment,
adult young and adolescents, bone marrow transplant
1. Introduction
Acute lymphoblastic leukemia (ALL) is an oncohematological disease caused by
genetic changes that alter the differentiation and proliferation of lymphocytes,
distinguished by the infiltration of bone marrow, blood, and other tissues by neo-
plastic cells of hematopoietic origin [1]. The pathophysiology of these disease
include causes for which, certain genes result affected in their function. Patients
could present the following symptomatology: fever, lymphadenopathy, coagulation
disorders, anemia, hepato-splenomegaly, weight loss, among others.
Another definition of ALL could be a disease caused by an acquired or congenital
injury to the hematopoietic cell DNA (the genetic material) developing in the bone
marrow, once these cells transform into a leukemic clone multiplies uncontrollably
and rapidly in billions of malignant cells called lymphoblasts that prevents the
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normal cellular production of leukocytes, platelets and red blood cells. As a result,
when a patient is diagnosed with acute lymphoblastic leukemia, the number of
healthy blood cells (red blood cells, white blood cells, and platelets) could be less
than normal, although it is not uncommon to see an exaggerated elevation of white
blood cells but all of them lymphoblasts.
It is more frequent in childhood than in adulthood, being the most common type
of leukemia in children, with a peak of incidence between the 2 and 4 years old.
When it appears in adulthood, it implies a worse prognosis.
2. Diagnosis by flow cytometry
There are a group of important cellular markers to make the diagnosis of B cell
lineage, those are: CD19, CD20, CD22, CD24, and CD79a. The principal and earlier
markers for lineage B cells are CD19, CD22 (membrane and cytoplasm respective)
and CD79a [1, 2]. The presence of either of these two markers, without further
differentiation markers, identifies the neoplastic cell as pro-B ALL (EGIL BI
subtype). Positivity of the CD10 antigen (CALLA) defines the neoplastic cell as
“common ALL” (EGIL B-II subtype). Cases with additional identification of the
cytoplasmic heavy Mu chain are classified as the pre-B group (EGIL B-III subtype),
while the presence of surface immunoglobulin light chains as mature B-ALL (EGIL
B-IV subtype) [3].
In recent years, the direct correlation between ontogenetic classification with
immunophenotypic expression by flow cytometry and cytogenetic or molecular alter-
ations in type B acute lymphoblastic leukemia has been described (Table 1) [3–6].
T-cell ALL constitutes 25% of adult ALL cases. Characteristic T cell markers are
CD1a, CD2, CD3 (membrane and cytoplasm), CD4, CD5, CD7, and CD8. CD2, CD5
and CD7 antigens are markers of immature T cells, but none of them is absolutely
lineage-specific, so the unequivocal diagnosis of T-ALL is based on the demonstration
of superficial / cytoplasmic CD3. In T-ALL CD10 expression is quite common (25%)
but non-specific, CD34 andCD13 and / or CD33myeloid antigens can also be expressed
by these cells. The recognized T-ALL subgroups: pro-T EGIL TI (cCD3 +, CD7 +), pre-
T EGIL T-II (cCD3 +, CD7 + and CD5 / CD2 +), cortical T EGIL T-III (cCD3 +, Cd1a +,
sCD3 + / -) and mature-T EGIL T-IV (cCD3 +, sCD3 +, CD1a) [3–7].
PRECURSORS ONTOGENICS INMUNOPHENOTYPE MOLECULAR CYTOGENETIC








Common CD10 (+++), CD 34(+),






Pre B CD 10(+), CD34(-),




Mature CD20(+), TdT(-), CD10
(+), CD34(-), k(+) o
λ(+)
rearregment of MYC, t(8;14), t(2;8),
t(8;22)
Table 1.
Immunogenetic classification of B ALL.
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The ontogenetic and immunocytogenetic correlation have particular importance
due to prognostic relevance in both B-cell and T-cell lymphoid leukemia. Table 2
shows the correlation between the different T cell-type leukemia.
3. Cytogenetic diagnosis
The karyotype alterations that could be found in ALL are numerical and struc-
tural changes as well, that have profound prognostic significance. Cytogenetics
analysis represents an important step in ALL classification. The conventional kar-
yotype can be useful in identifying recurring translocations, as well as in the iden-
tification of gain or loss of chromosomal material; However, the biggest limitation
of this technique is the requirement of the cell to enter in metaphase, what is
necessary for the obtaining of the material for the analysis of chromosomes. In such
cases the technique of fluorescence in situ hybridization (FISH) can allow direct
detection and visualization of virtually all investigated chromosomal abnormalities
in ALL, with a sensitivity near of 99%, finally, comparative genomic hybridization
of matrices (matrix-CGH, a-CGH) and matrices of single nucleotide polymor-
phisms(SNPs) can allow the identification of cryptic and/or submicroscopic
changes in the genome [8, 9].
3.1 Cytogenetic/genetic risk groups
The aberrations with a good prognosis are: del(12p), t(12p) / t(12; 21) (p13; q22)
t(10; 14) (q24; q11) in ALL of lineage B. These abnormalities are relatively rare in
adults compared to childhood with ALL.
Aberrations associated with intermediate risk include the normal diploid subset
plus cases of hyperdiploidy and various other recurrent or random chromosomal
abnormalities.
Other aberrations such as isolated trisomy 21, trisomy 8, and perhaps del(6q)
and t(1; 19) (q23;p13) / E2A-PBX1 may constitute an intermediate-high risk group;
Recent evidence suggests that the previously poor prognosis reported for t (1, 19)
(q23; p13) / E2A-PBX1 could be outweighed by some current therapeutic
approaches [10, 11]. Other newly identified aberrations in the intermediate-high
risk group are iAMP21 12 and IGH rearrangements, including CRLF2 [12, 13].
Finally, patients with t(9; 22) (q34; q11) or BCR-ABL1 rearrangement with
positive FISH test (Philadelphia + ALL), t (4; 11) (q21; q23) or MLL rearrangements
PRECURSOR ONTOGENICS INMUNOPHENOTYPE MOLECULAR/
CYTOGENETIC
Pro T (T I) CD2(-), CD5(-), CD8(-), CD4
(-), TdT(++), CD34(+/-)
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(+), CD1a(-), mCD3(-)
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Immunogenetic classification of T cell.
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at 11q23, monosomy 7, hypodiploidy (and the closely related near triploid group)
fell into the high-risk cytogenetic category, with a disease-free survival (DFS) rate
of approximately 25%, or 10% in the specific case of Phi + ALL prior to introduction
of tyrosine kinase inhibitors (TKI) [14, 15]. The presence of the Phi + chromosome
in ALL can constitute 25–50% of CD10 + or pre-B cases and represent the most
frequent alteration in adult and elderly patients, found in more than 50% of cases in
the 6th decade of life [16]. Secondary chromosomal abnormalities in addition to t(9;
22) (q34; q11) may worsen the prognosis [17] however this has not yet been proven
in the TKI era [18]. Currently the most group with the most unfavorable prognosis
among cases with known genetic / molecular aberration is represented by t(4; 11)
(q21; q23) with MLL1 rearrangement unless an allogeneic hematopoietic stem cell
transplantation is performed [19].
Some other karyotypes alterations are exclusive to specific ALL syndromes.
Translocations involving chromosome 8 (MYC gene), as well as t (8; 14) (q24; q32)
(90% of cases), t (8; 22) (q24; q11) (10% of cases) and t (2;8) (rarely observed) are
practically present in 100% of cases of mature B-ALL with L3 / Burkitt morphology
and immunoglobulins in the clonal surface. Typical cytogenetic aberrations are also
found in the T lineage, the most frequent involve resection points of 14q11, for
example, t (10; 14) (q24; q11), t (11; 14) (p13; q11) and others, the presence of t (8;
14) with resection points at q24; q11 (q24; q32 in line B ALL) in T cell ALL is
associated with aggressive lymphomatous presentation [20–22].
An interruption in IKZF1 encoding the Ikaros transcription factor has been fre-
quently observed in ALL with BCR / ABL rearrangement (80% of cases). The IKZF1
mutation predicts poor outcome in the treatment of ALL, Phi+ or not [13, 23–25].
By integrating genome-wide technologies the “BCR / ABL-like” subgroup has
been suggested and identified in adult and child populations [26, 27] and represents
approximately 15% of ALL ontogeny B cases. This subgroup It is characterized by a
gene expression that is similar to that of BCR/ABL + patients, with frequent detec-
tion of the IKZF1 mutation and CRLF2 rearrangements but with where abysmal
differences in the outcomes. Other mutations and / or rearrangements that activate
tyrosine kinases has also been revealed as poor prognosis factor such as
rearrangement of IGH-CRLF2, NUP214-ABL1, EBD1-PDGRB, BCR-JAK2 fusions
and STRN3 JAK2, which have been associated with a very poor prognosis [28].
Hypodiploid ALL, considered a high risk factor has been extensively evaluated
in pediatric ALL [29] Alterations involving tyrosine kinase receptors and RAS gene
signaling (i.e., NRAS, KRAS, FLT3, and NF1) can be detected in up to 70% of
haploid cases, while hypodiploid cases are characterized by lesions involving mem-
bers of the Ikaros family, particularly IKZF2 and by TP53 interruptions which can
be identified in 91.2% of these. In adult ALL, these cases are characterized by non-
random chromosome loss and CDKN2A / B with locus deletion as the only recurrent
abnormality; As previously reported, in children these cases often harbor TP53
mutations [30].
The TP53 mutation is detected in 6.4% of all ALL cases and a correlation with a
worse result has been demonstrated. In adults, TP53 mutations are identified at
diagnosis in 8.2% of cases (11.1% of T-ALL and 6.4% of B-ALL), and are preferably
identified without molecular aberrations and are associated with refractoriness to
chemotherapy [31, 32].
In T cell-ALL, well-recognized aberrations are: Rearrangement of the T-cell
receptor (TCR) gene, chromosomal deletions and focal gene deletions, in addition,
chromosomal rearrangements can also lead to fusion genes in the framework of
Chimeric proteins with oncogenic properties such as thePICALM-MLLT10,
NUP214-ABL1 fusion for medin episomes, EML-ABL1, theSET-NUP214 fusion and
MLL-type genetic rearrangements have uncertain significance [33, 34].
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A large set of mutations in T cell-line ALL has been identified by sequencing
techniques including NOTCH1, FBW7, BCL11B, JAK1, PTPN2, IL7R and PHF6,
some of them have recognized prognostic importance, while others require further
investigation. In fact, NOTCH1 and / or FBW7 mutations that occur in more than
60% and around 20% of cases, respectively, are generally associated with a favor-
able outcome. A new prognostic model has been recently proposed defining as low
risk those with NOTCH1 and FBW7 mutations and those with lesions involving
RAS/PTEN as high-risk. JAK1 mutations, which increase JAK activity and impair




Hypodiploidy (>50 chromosomes) – 7% 25%











t(5;14) (q31;q32) IL3-IGH < 15 <1%
t(8;14), t(2;8), t(8;22) c-MYC 4% 2%




t(5;14) (q35;q32) HOX11L2 1% 35
t(11;14) (q11)(p13;q11) (p15;q11) TCR y
TCR
20-25% 10-20%
BCR-abl1-like/Ph-like Multiple 10-30% 15%
LLA-B con iAMP21 RUNX11 – 2%
ETP Multiple 2% 25%
Ikaros IKZF1 25-35% 12-17%
Table 3.
Frequency of Chromosomic and molecular alterations by age group.
Risk Cytogenetic alterations
Good • Hypodiploidy (51-65 chromosomes)
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proliferation and survival, have been associated with refractoriness of chemother-
apy and should be considered as poor prognosis markers [35, 36].
Recurrent chromosomal and molecular abnormalities characterize ALL subtypes
in adults and children (Table 3) and often provide prognostic information that can
influence risk stratification and treatment decisions (Table 4). The frequency of
certain subtypes differs between adult and child ALL, what partially explains the
difference in clinical outcomes between patient populations [6, 30, 34, 36].
The most recent classification of the World Health Organization (WHO) for
acute lymphoblastic leukemia ins shown in Table 5.
4. Treatment
The evolution in treatment of patients with ALL has progressed over time, this
in order to achieve better survival, relapse-free rates and the quest to achieve cure.
We will divide this issue into two large groups: AYA group (adolescents and young
adults) and the group of people over 40 years old; and subdivided focusing on
status of Philadelphia chromosome (positive and negative).
Chemotherapy treatment is divided into treatment phases with different goals:
[38, 39].
Induction: it is the phase that seeks to achieve remission normalizing the
parameters of the blood count (Hb >10 gr/dl, Neutrophils >1000 /mm3, platelets
>100,000/mm3) as well normalization of the organs affected by diagnosis (liver,
kidney, lung).
Consolidation: in this phase, the aim is to keep the patient in remission and
achieve a negative minimal residual disease (MRD) that will impact the prognosis.




B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1
B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged
B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1);ETV6-RUNX1
B-lymphoblastic leukemia/lymphoma with hyperdiploidy
B-lymphoblastic leukemia/lymphoma with hypodiploidy
B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH
B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1
Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like
Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP21
T-lymphoblastic leukemia/lymphoma
Provisional entity: Early T-cell precursor lymphoblastic leukemia
Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma
Modified of D´Angelo, 2006 [37].
Table 5.
WHO classification of lymphoblastic leukemia.
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5. Treatment of the AYA group
This group is considered as a “superimposed” population since pediatric
schemes have improved their degrees of response compared to adult designed
schemes. Initially, the treatment regimens in this group of patients were based on
regimens for adults, showing complete remissions in a low percentage, a couple of
examples are the UKALLXII/ECOG [41] case study that reported complete remis-
sion (CR) nearly 51% after 1 chemotherapy cycle with increase to 91% after 2
induction cycles and the CALGB8811 [42] study that reported RC of 62–86% after 1
and 2 cycles of induction to remission respectively; On the other hand, the LALA-94
[43] study reported CR rate of 72% after one treatment cycle up to 84% after 2
treatment cycles, thus we have to mention the Hyper-CVAD scheme with a CR rate
in the first cycle reported in 81% with increase after 2 cycles to 92% [44]; the
DFCI45 pilot study showed an RC of 82% in the first induction cycle. Due to the
above, it’s clear that treatment schemes based on adults’ schemes are ineffective to
achieve CR, for these reasons the AYA Group was separated looking for different
treatment schemes which includes two large groups, those based on pediatric
schemes with expansion in the group of age and modified pediatric inspiration
schemes (Tables 6 and 7).
By reviewing the pediatric regimens with extension to the age group of treat-
ment was possible to increase the degree of response in this group classified as AYA;
in adult regimens, complete remissions ranging from 51% to a maximum of 82%
were reported after 1 cycle of treatment, however, in Table 1 we observe that
pediatric regimens in general achieved a higher percentage of complete response or
remission after applying 1 cycle of induction, showing with the highest degree of
complete response in 98% of the cases for the studies: TOTAL TERAPY IV, 46
PETHEMA ALL 96.47 DCOG, 58 ALL97.59, however, it should be noted that the












CCG 1961 262 16-21 95 5/72 5/78 [38]
DFCI9101/9501 51 15-18 94 5/78 5/81 [40]
UKALL 2003 229 16-24 97 5/72 5/76 [39]
TOTAL TERAPY XV 45 15-81 98 5/86 5/88 [45]
PETHEMA ALL 96 81 15-30 98 6/61 6/69 [46]
HOVON (FRALLE 93) 54 17-40 91 2/66 2/72 [47]
NOPHO 2008 221 18-45 NR 5/74 5/78 [48]
FRALL 2000 186 15-19 96 5/74 5/80 [49]
INTERGROUPC10403 296 17-39 NR 2/66 2/79 [50]
FRALLE93 77 15-20 94 5/67 NR [51]
DCOG 47 15-18 98 5/69 5/79 [52]
ALL97 61 15-17 98 5/65 NR [53]
AIEOP 150 14-18 94 5/67 5/67 [54]
CR: Complete Remission, Ref. Reference, DFS: Disease Free Survival, OS: Overall Survival, NR: Not Reported.
Table 6.
No comparative studies of pediatric regimens.
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PETHEMA ALL 96.47 study, which shows a reported follow-up at 5 years with
evidence of DFS of 61% OS of 69% at 6 years. On the other hand, it is important to
mention that the Intergroup C1040351 study observed a 2-year DFS of 66% and an
OS of 79%. In all the groups referred to in Table 8, the degree of CR registered was
greater than 90%, but with different DFS and OS times, the longest DFS time for
the DCOG study, which was 69% at 5 years and OS of 79% at 5 years.
Of the pediatric inspiration schemes, we refer to those registered in Table 9, all
of them report CR greater than 90%, with the exception of studies DFCI01–17552












DFCI 01-175 74 18-50 86 4/58 4/67 [55]
MODIFIED DFCI
91-01
42 18-35 98 3/77 3/83 [56]
GRAALL2003/2005 502 15-35 95 5/59 5/65 [57]
GMALL 07/03 887 15-35 91 5/61 5/65 [58]
MODIFIED TPOG 35 15-39 89 2/47 2/50 [59]
LALIN 20 15-25 90 5/70 NR [60]
NOPHO-92 144 10-14 99 5/65 NR [61]














Hyper-CVAD 185 >60 91 5/39% 5/10 [62]
SMOG 8419 85 50-84 41 5/32 5/<10 [63]

















PETHEMA ALL96 33 56-67 58 2/39 2/46 [66]
MRC UKALLXII/ECOG2993 100 55-64 70 5/19 5/21 [67]








































ALL-07FRAIL 72 57-89 54 6.9 month 7.6 month [71]
CR: Complete Remission, Ref. Reference, DFS: Disease Free Survival, OS: Overall Survival, NR: Not Reported.
Table 8.
Treatment schemes for ALL in adults.
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respectively, is recorded. Likewise, the DFS reported in the MODIFIED TPOG
group is lower, being 47% of the cases at 2 years. In this same table we observe
the two studies with the largest number of patients, the GRAALL2003 / 200,554
study with a number of subjects analyzed of 502 cases and for the GAMALL55
study 887 cases, with a similarity in the DFS reported for the GRAALL2003 / 2005
of 59% at 5 years and for GMALL07 / 03 from 61% at 5 years and similar OS in both
groups from 65% at 5 years; the aforementioned has generated improvement in
responses and survival in the AYA groups, so the current recommendations
are aimed at treating pediatric schemes or modified schemes of pediatric-inspired
protocols.
Those patients over 40 years old are considered as “adults” an represent totally
different group when comparing with the pediatric and AYA groups when talking
about prognosis and treatment. The age by itself is a conditioning factor for a lower
response rate, lower DFS, and poorer OS compared to the AYA group, this data is
summarized in Table 8. This group have hematological remission variable and
those with lesser degree of Response rate are adults over 65 years, with a percentage
of CR ranging from 41 to 60% according to the ALL-07FRAIL72 studies and the
SMOG 841964 study. As illustrated in Table 3, in the Edouard Herriot Lyon Hospi-
tal, the population of 35–60 years old reached a CR of 85% but this was lower in the
group over 60 years with CR reported in 58% [69]; as well as the study of the MD
Anderson with the HyperCVAD [62] scheme where the age groups of 30 to
49 years, 50 to 59 years and over 60 years reached a CR of 98%, 83%, 79% respec-
tively [70]. In the same way, the DFS and OS for the Hyper CVAD group of the
GIMEMA study 028865 was lower in the older groups, 39% at 5 years and an OS
with a longer duration of 27% at 9, in general we conclude that the older age could
be related to lower rate of CR, DFS and OS.
All those previously described have been mainly in the groups cataloged as Phi
negative ALL, as they are not carriers of the BCR / ABL oncogene, however, in the












GMALL (Imatinib) 28 54-79 96 2/19 2/42 [72]
PETHEMA ALL0PH07
(Imatinib)
53 56-88 87 38months 37.3 months [73]
HyperCVAD + Imatinib 54 17-84 93 5/43 5/35 [74]
GIMEMA LAL0201-B
(Imatinib)
29 61-83 100 1/48 1/74 [75]
EWAL-PH-01 (Dasatinib) 71 59-83 96 5/27 5/36 [76]
GIMEMA LAL1205
(Dasatinib)
53 18-77 100 2/51 2/69 [77]
HyperCVAD plus Dasatinib. 72 21-80 96 5/42 5/52 [78]
EWALL-PH-02 Nilotinib 65 55-85 87 NR NR [79]
Korean study Nilotinib 90 17-77 91 2/72 2/72 [80]
HyperCVAD + Ponatinib 37 27-55 100 2/81 2/80 [81]
GIMEMA + Ponatinib 42 27-85 91 3/69 3/83 [82]
CR: Complete Remission, Ref. Reference, DFS: Disease Free Survival, OS: Overall Survival, NR: Not Reported.
Table 9.
ALL Phi positive treatment.
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Table 9, where the different percentages of response between these and those Phi
negatives are observed.
In the GMALL73 study the benefit of adding a tyrosine kinase inhibitor (TKI) to
non-intensive regimens in elderly patients was initially observed. In this study a
group was randomized to receive chemotherapy (CT) + TKI vs. CT, and was
observed that adding an TKI achieved a CR of 96%, the double from the RC of 50%
seeing in patients who were not treated with imatinib. In this patient group it is
striking that adding TKI to a conventional chemotherapy scheme offers the benefit
of even higher CR than those presented in populations older than 40 years, as
reported in the studies of the Italian group (GIMEMA, LAL0201-B and GIMEMA
LAL1205) [75, 77]with CR of 100% with 1st and 2nd generation inhibitor of TKI,
however, the DFS and OS were brief in both groups, being higher in the group that
received dasatinib (2nd generation TKI) as induction therapy and with a younger
population that predicts the higher degree of response. It is worth mentioning that
the second-generation TKI dasatinib has Central Nervous System (CNS) penetra-
tion showing improved response and survival of cases with CNS infiltration com-
pared to imatinib that fails to cross the blood–brain barrier. Table 4 records the
treatment given by the MD Anderson group, which showed that adding a 3rd
generation TKI as ponatinib to the HyperCVAD scheme achieved 100% CR in the
group aged 27 to 55 with DFS and OS at 2 years of 81 and 80% respectively [81].
It should be mentioned that ponatinib has good CNS penetration as does dasatinib,
however ponatinib is indicated in patients with the T315I resistance mutation.
A meta-analysis of 15 studies with a total of 11,040 patients with ALL Phi
positive shown that the highest prevalence of Phi positive is seeing in those between
11 and 40 years old (25.8% to 26.2%.) By age subgroup the reported prevalence was:
1–10 years 15.6%, 10–20 years 25.6%, 21–40 years of age 26.2% and in the group
over 40 years of age 16.9%. In this meta-analysis, the overall 5-year survival rate
was 42.8% (CI 95% CI, 23.9–64.1, I2 93) [83].
6. Prophylaxis to CNS
Intrathecal chemotherapy is pivotal in the treatment of ALL since the CNS is a
site of relevance in this pathology. In adult ALL involvement of the CNS at diagno-
sis is reported in 5–7% of cases, mainly with meningeal involvement. The risk
factors related to initial infiltration are elevated Lactic Dehydrogenase (LDH),
hyperleukocytosis and ALL B subtype at diagnosis, the latter showing CNS involve-
ment in up to 18% of cases. Other factors that contribute to the initial infiltration
are increased blast replication rate, mediastinal mass, and positive Phi [84]. These
same factors contribute to the early relapse of the disease, systemically or in isola-
tion to the CNS. For the diagnosis of infiltration, the microscopic examination of
cerebrospinal fluid (CSF) obtained from a lumbar puncture continues to be the
standard and classified the cases into risk groups according to the number of
leukocytes, and the presence of blasts (Table 10) and the nature of the lumbar
puncture, as well as determination by flow cytometry.
Traumatic Lumbar puncture (TLP) is defined as a result of CSF with erythrocyte
count>10 /uL. The Stevenherz/Bleyer algorithm evaluates traumatic puncture if the
patient has leukemic cells in peripheral blood and the lumbar puncture is traumatic
and contains >5 leukocytes/uL and blasts, the following algorithm should be
followed to distinguish between CNS2 disease and CNS3: CSF leukocytes/
erythrocytes >2 x leukocytes in blood/red blood cells [84, 85].
Effective prophylaxis to prevent CNS relapse is an essential part of ALL
regimens, the most used modalities are based on CNS irradiation, intrathecal
10
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chemotherapy with a single drug or with steroid-based triplet plus cytarabine and
methotrexate at same time as systemic CT is being administrated. With these
measures the relapse rate can be reduced from 10 to 5%. Irradiation as a single dose
of 24 Gy is recommended as unique therapy to the skull without involving the
neuroaxis to avoid cytopenia associated with concurrent CT [86]. In cases of ALL
Phi +, although dasatinib and ponatinib are not part of prophylaxis therapy these
have been shown to cross the blood–brain barrier and secondarily reduced the risk
of isolated relapse to the CNS [87, 88].
7. Hematopoietic stem cell transplant
Hematopoietic stem cell transplant (HSCT) in patients with Acute Lymphoblas-
tic Leukemia is a therapeutic option in those with high risk disease that have
reached complete response (CR) and those who are candidates by the Predictive
Models of Risk (Disease Risk Index (DRI), EBMT Risk Score, HCT-Comorbidity
Index). the patients could be classified in 3 different risk groups (0 points = low
risk, 1–2 points = intermediate risk, ≥ 3 = high risk) and this correlated with two
years NRM (non relapse mortality (Table 11) [90–93].
The modality of transplant recommended is allogenic after the first complete
response (CR1) in high-risk patients (Table 12) and in patients with second
complete response (CR2) [90].
Autologous HSCT is not recommended for an adult with ALL. It could be
possible in high-risk patients with negative minimal residual disease (MRD) that are
not considered for allo-HSCT, but there is insufficient data to support this option,
including Phi + ALL [91].
7.1 Indication for the different modalities of allo-HSCT
It is preferred a matched sibling donor or an unrelated donor very well matched,
these options are considered equivalent in terms of results [91, 92].
Haploidentical transplant is always an option in patients without a matched
donor, this type of transplant is nowadays frequently used because it allows
almost all patients in need for an allo-SCT to undergo allo-SCT without a
matched-donor [96].
7.2 Conditioning
The choice of conditioning is based on the patient’s physical status, for those fit
without relevant comorbidity the recommended regimens are the combination of
fractionated TBI (Total Body Irradiation) 12Gy in 6 fractions, plus
Classification Lymphoblasts in CSF Leucocytes in CSF
SNC 1 None
SNC 2 Present <5
SNC 3 Present ≥5
TLP Present Variable
CSF, cerebrospinal fluid; CNS, central nervous system; traumatic lumbar puncture (TLP).
Table 10.
Classification of the CNS infiltration according to the CSF characteristics.
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Cyclophosphamide (Cy) 120 mg/kg or Etoposide (VP) 60 mg/kg. The regimens
with TBI seem to have better anti-leukemic activity than busulfan-based
regimens [97].
For elderly patients should be considered reduced conditioning regimens as for
patients with contraindications for myeloablative regimens [92].
For patients with an haploidentical donor the used scheme is: Cy 14.5 mg/kg/day
IV on days 6 and  5, fludarabine 30 mg/m2/day IV on days 6 to 2, and
200 cGy of TBI on day 1, on days +3 and + 4, 50 mg/kg Cy with Mesna [98, 99].
Other regimens for transplant with haploidentical donor recommended by the
Acute Leukemia Working Party of EMBT are: 1) Myeloablative regimen TBF (thio-
tepa 10 mg/kg, fludarabine 150 mg/m2, busulfan 9.6 mg/kg IV. 2) RIC (reduced-
intensity chemotherapy) Thiotepa 5 mg/kg and busulfan 6.4 mg/kg. ATG and
Cyclophosphamide are used as prophylaxis for Graft versus Host Disease (GVHD)
at doses of ATG 10 mg/Kg (total dose), or Cy 50 mg/kg +3 and + 4 [96].
Comorbidity Points Comorbidity Points
Liver disease
Liver cirrhosis, bilirubin >1.5xULN, or
AST/ALT >2.5xULN
3 Obesity
BMI of > 35 for adults
1
Severe pulmonary
DLco and/or FEV1 ≤ 65%, dyspnea at rest
oroxygen at home
3 Hepatic Mild
Chronic hepatitis, bilirubin>ULN to









psychiatric consult and/or treatment
at the time of HCT
1
Heart valve disease
Diagnosed (except mitral prolapse)
3 Cerebrovascular Disease




DLco and/or FEV1 66–80% or minimal stress
dyspnea
2 Diabetes




Creatinine >2mg/dl, dialysis, or previous
kidney transplant
2 Inflammatory bowel disease
Crohn’s disease or ulcerative colitis
1
Rheumatologic
SLE, RA, polymyositis, mixed CTD, and
polymyalgia rheumatica
2 Coronary artery disease
congestive heart failure, myocardial





Atrial fibrillation or flutter, sick




Documented infection or fever of unknown
etiology requiring antimicrobial treatment
before, during and after the start of
conditioning regimen
1 Age ≥ 40 1
EF = ejection fraction; ULN= upper limit of normal, AST = aspartate aminotransferase, ALT = alanine
aminotransferase, BMI=body mass index, SLE = systemic lupus erythematosus, RA= rheumatoid arthritis,






7.3 Maintenance post allo-HSCT
It is recommended for patients with Ph +, maintenance with TKI after allo-
HSCT. The optimal treatment duration has not been defined. The described options
are continuing the treatment until MRD negativity is confirmed by three consecu-
tive tests or sustained for at least three months, or TKI administration for at least
one year of continuous PCR negativity, and if a single positive result, then reset the
treatment period [100].
7.4 Status of minimal residual disease before HSCT
It is demonstrated that the presence of MRD positivity at the time of HSCT is a
significant risk for relapse after the procedure; this asseveration applies for both




It is a bispecific T-cell engager antibody construct that binds simultaneously to
CD3-positive cytotoxic T cells and CD19-positive B cells, this reaction allows the
patient’s endogenous T cells to recognize and eliminate CD19-positive ALL blasts.
It is indicated for the treatment of B- ALL in the first or second complete
remission with MRD >/= 0.1% and in B-ALL relapse or refractory in adults and
children.
In the TOWER study, eligible patients with pretreated B-ALL were randomly
assigned to receive Blinatumomab or Standard Chemotherapy. The overall survival
was significantly better in patients treated with Blinatumomab compared with
those of the standard group. The median OS was 7.7 months (95% confidence
interval [CI], 5.6 to 9.6) in the blinatumomab group versus 4.0 months (95% CI, 2.9
High Risk
Cytogenetics Hypodiploidy (< 44 chromosomes)
t(9:22) (q34;q11.2):BCR-ABL1




High WBC count at diagnosis >30 x 109 in B-ALL
>100 x 109 in T-ALL
ALL subtypes T-cell precursor ALL
High-risk genetics IKZF1 deletion in B precursor ALL, unmutated NOTCH1, Ph-like.
MRD >1X104 after two courses of therapy, some groups post-induction.
CNS disease Central Nervous System involvement
Immunophenotype Pro-B/early and mature-T
Time to CR >1 cycle
Table 12.
High Risk Patients [91, 92, 94, 95].
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to 5.3) in the chemotherapy group (hazard ratio for death, 0.71; 95% CI, 0.55 to
0.93; p = 0.01 [104].
8.2 Inotuzumab ozogamicin (InO)
It is a humanized anti-CD22 monoclonal antibody conjugated to calicheamicin, a
potent cytotoxic antibiotic compound that induces double-strand DNA breaks. It is
utilized in patients with relapsed or refractory (R/R) B-ALL [105].
Katarjian H. and cols published a phase 3 trial (INO-VATE ALL) where ran-
domly assigned adults with R/R ALL to receive either inotuzumab ozogamicin or
standard intensive chemotherapy. The rate of complete remission was 80.7%
in the inotuzumab ozogamicin group than in the standard therapy group, 29.4%
p < 0.001. In the survival analysis OS of 5.0 months vs. 1.8 months (HR0.45
[97.5% CI, 0.34 to 0.6)]; p < 0.001. The veno-occlusive disease occurred more
frequently in the InO group [106].
8.3 Tisagenlecleucel
It is a CD19-directed, genetically modified, autologous T-cell immunotherapy. It
is prepared from an apheresis collection of the patient’s peripheral blood mononu-
clear cells. The autologous T cells are transduced using a lentiviral vector to express
an anti-CD19 chimeric antigen receptor (CAR) [107]. Tisagenlecleucel was the first
gene-modified cell therapy approved by the FDA for children and young adults
with relapsed or refractory B-cell ALL.
These have proven highly efficient at inducing MRD-negative remissions. A
CAR induced remission could offer a window to proceed to allo- HSCT [107, 108].
Maude and cols published this trial of tisagenlecleucel in children with R/R B-ALL,
the overall remission rate was 81%. All patients with complete remission were nega-
tive forMRD. The rate of relapse-free survival in patients with a response to treatment
was 80% at 6months and 59% at 12months. Neurologic events occurred in 40% [108].
9. Minimal residual disease (MRD)
In the last decade, the measurement of minimal residual disease has become a
necessary tool in the follow-up of patients since its impact on progression-free
survival and overall survival has been demonstrated in multiple studies, that leads it
to be currently an indicator of treatment for patients with acute leukemia.
There are several ways of measurement of MRD and each one presents different
sensitivity as describe: New Generation Sequencing (NGS) present a sensitivity of
106; Flow cytometry with a 104 sensitivity for cytometers of 6 colors and 106 for
cytometers of 8 colors or more; PCR for specific genes 105 of sensitivity. However,
to achieve these sensitivity results, it is necessary to perform them on bone marrow
samples considered in morphological remission [89, 109].
We have already discussed the prognostic value of having a negative MRD. The
GRAALL group demonstrated that the presence of negative MRD at the end of
induction was a better prognostic marker than the conventional ones, like the
achievement of CR at first line therapy a transplantation in patients with pediatric
schemes [109, 110].
In a meta-analysis published in 2017, including 13,637 patients in total, the
progression-free survival for the pediatric group was 77% at 10 years in patients
with negative MRD, and 64% for adults, while progression free survival for patients
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